Corvus Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 20, 2019. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Burlingame, California. As of the record date (April 24, 2019), there were 29,326,900 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
Two proposals were voted upon at the Annual Meeting, with 27,021,417 shares voted in person or by proxy:
- Proposal 1: Election of Directors
- Ian T. Clark: 17,741,792 votes For; 7,185,155 votes Withheld.
- Elisha P. (Terry) Gould III: 22,535,894 votes For; 2,391,053 votes Withheld.
- Peter Thompson, M.D.: 22,531,875 votes For; 2,395,072 votes Withheld.
- All three Class III director nominees were elected to serve until the 2022 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Accounting Firm
- PricewaterhouseCoopers LLC was ratified for the fiscal year ending December 31, 2019.
- Votes For: 24,712,924; Votes Against: 4,403; Abstain: 2,304,090.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the newly elected directors' tenure and any potential conflicts of interest.
- Confirm the high level of broker non-votes (2,094,470) on the director election and its impact on corporate governance.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 24, 2019) for detailed background on the director nominees and the rationale for the accounting firm selection.
- Note that the Company has elected not to use the extended transition period for complying with new financial accounting standards.